Ampliphi Biosciences (APHB) Stock Price, News & Analysis

Company Overview

AmpliPhi Biosciences Corporation was a biotechnology company focused on developing bacteriophage-based therapeutics. Bacteriophages are viruses that selectively infect and destroy specific bacteria, and the company’s programs were aimed at addressing bacterial infections, including those caused by antibiotic-resistant pathogens.

Its development pipeline included AB-SA01, an investigational phage therapy targeting Staphylococcus aureus, and AB-PA01, designed to target Pseudomonas aeruginosa. These programs were being evaluated for potential use in serious and chronic infections, including respiratory infections associated with cystic fibrosis.

AmpliPhi operated as a clinical-stage biotechnology company and primarily focused on advancing its phage therapy candidates through research and clinical development rather than marketing approved products. In 2019, the company changed its name to Armata Pharmaceuticals, Inc., reflecting its continued focus on precision phage therapeutics.

Key Stats

• Today's Range: $3.56 to $3.81
• 50-Day Range: $3.62 to $5.84
• 52-Week Range: $0.15 to $1.37
• Volume: 100,793 shs
• Average Volume: 842,200 shs
• Market Capitalization: $125.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 3/25/2019
• Today: 9/27/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSEAMERICAN:APHB
• Previous Symbol: AMEX:APHB
• CIK: 921114
• Web: www.ampliphibio.com
• Phone: +1-804-8272524
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 33,469,000
• Free Float: N/A
• Market Cap: $125.17 million
• Optionable: Not Optionable
• Beta: N/A